Um die volle Funktionalität der Webseite nutzen zu können, müssen Sie JavaScript in ihrem Browser aktivieren.

DAX19.390,04+0,87 %

Gold2.656,990,00 %

Öl (Brent)79,04-0,57 %

Dow Jones42.865,63+0,97 %

US Tech 10020.269,38+0,14 %

EUR/USD1,09379+0,02 %

Top 15 der gesamten Suchanfragen der letzten 7 Tage

Login

Virpax Pharmaceuticals Aktie

Aktie

ISIN: US9282512063 SYM: VRPX Land Flagge US

USA

Zur Watchlist hinzufügen Zum Portfolio hinzufügen

Zum Portfolio hinzufügen

0,4744

USD

+3,13 %

+0,0144 USD

Letzter Kurs 02:00:00 NYSE

Geldkurs

11.10.24

0,4388

USD

100 STK

Briefkurs

11.10.24

0,5000

USD

600 STK

Virpax Pharmaceuticals Aktie kaufen

Neueste Nachrichten

Virpax Pharmaceuticals Reports 2024 Second Quarter Results and Recent Developments 13.08.24 · Business Wire (engl.) · Virpax Pharmaceuticals
Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference August 14-15 08.08.24 · Business Wire (engl.) · Virpax Pharmaceuticals
Virpax Regains Compliance with Nasdaq Minimum Bid Price 24.07.24 · Business Wire (engl.) · Virpax Pharmaceuticals
Virpax Announces Positive Results of Swine Model Pilot Study for Probudur 10.07.24 · Business Wire (engl.) · Virpax Pharmaceuticals
Virpax Pharmaceuticals Secures $2.5 Million Loan Financing and an Agreement with an Institutional Investor to Negotiate Additional Funding 08.07.24 · Business Wire (engl.) · Virpax Pharmaceuticals
Virpax Pharmaceuticals to Present at 2024 BIO International Convention 29.05.24 · Business Wire (engl.) · Virpax Pharmaceuticals
Virpax Announces Pricing of $2.25 Million Public Offering 15.05.24 · Business Wire (engl.) · Virpax Pharmaceuticals
Virpax Pharmaceuticals Reports 2024 First Quarter Results and Recent Developments 13.05.24 · Business Wire (engl.) · Virpax Pharmaceuticals
Virpax Announces Results of Maximum Tolerated Dose Study for Probudur 30.04.24 · Business Wire (engl.) · Virpax Pharmaceuticals
Virpax Pharmaceuticals Reports 2023 Year-End Results 26.03.24 · Business Wire (engl.) · Virpax Pharmaceuticals
Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price 27.02.24 · Business Wire (engl.) · Virpax Pharmaceuticals
Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc. 27.02.24 · Business Wire (engl.) · Virpax Pharmaceuticals

1
2

Meistgelesen

12 Monate

Virpax Announces Positive Results of Swine Model Pilot Study for Probudur 164 Leser
Virpax Pharmaceuticals Secures $2.5 Million Loan Financing and an Agreement with an Institutional ... 140 Leser
Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum ... 136 Leser
Virpax Pharmaceuticals Reports 2024 First Quarter Results and Recent Developments 132 Leser
Virpax Pharmaceuticals Reports 2023 Third Quarter Results and Recent Developments 124 Leser
Virpax Announces Results of Maximum Tolerated Dose Study for Probudur 120 Leser
Virpax Pharmaceuticals Announces Results of Special Shareholders Meeting 116 Leser
Virpax Pharmaceuticals to Present at 2024 BIO International Convention 116 Leser
Virpax Pharmaceuticals Announces Leadership Transition 112 Leser
Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference August 14-15 112 Leser